Contains 21-100 Amino Acids (c07k-7/10) Patents (Class 930/DIG820)
  • Patent number: 5847078
    Abstract: A physiologically active polypeptide, BUF-3, having the ability to differentiate and maturate human leukemia cells into normal cells and of accelerating the formation of erythroblasts is disclosed. The polypeptide has a molecular weight of 16.+-.1 Kd as determined by SDS-electrophoresis in the presence of 1% mercaptoethanol, or 25.+-.1 Kd, as determined by SDS-electrophoresis in the absence of mercaptoethanol.
    Type: Grant
    Filed: March 3, 1995
    Date of Patent: December 8, 1998
    Inventors: Yuzuru Eto, Tomoko Tsuji, Satoshi Takano, Misako Takezawa, Yasunori Yokogawa, Hiroshiro Shibai
  • Patent number: 5446130
    Abstract: Peptide derivatives of the following general formula (I): ##STR1## wherein AAA is deletion or Ser, BBB is deletion or Glu, CCC is deletion, Ile, Phe, Leu, cyclohexylalanine, D-alle or Lys substituted at the .epsilon.-position by C.sub.6 --C.sub.18 alkylcarbonyl group, DDD is Gly or Gln, EEE is Leu, Nle or Phe, FFF is Met, Leu or Nle, GGG is Ala, Ser Leu, Asn, Asp or Gln, HHH is Leu, Glu or Lys, III is His, Lys or Arg, JJJ is His, Lys or Arg, Xaa is Ala modified at the carboxy terminal with an amino group, provided that CCC and DDD may independently be modified at the amino terminal by C.sub.2 --C.sub.
    Type: Grant
    Filed: September 13, 1994
    Date of Patent: August 29, 1995
    Assignee: Mitsubishi Kasei Corporation
    Inventors: Tatsuhiko Kanmera, Akihisa Mori, Yoshihide Nakao, Toshihiko Minegishi
  • Patent number: 5317010
    Abstract: Analogues of bovine and human parathyroid hormone, wherein twenty-fifth, twenty-six and twenty-seventh positions of the natural hormone, Arg-Lys-Lys- each have been substituted with Ala, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val have been found to retain bone cell effect with minimal effects on blood pressure and smooth muscle, including cardiac muscle. It has further been found that this effect can be obtained by using a synthetic PTH containing only the first 34 amino acids of PTH, with substitution at the twenty-fifth, twenty-sixth and twenty-seventh amino acids as described. These analogues of PTH also are effective in the treatment of osteoporosis and other bone diseases.
    Type: Grant
    Filed: October 10, 1991
    Date of Patent: May 31, 1994
    Assignee: Peter K. T. Pang
    Inventors: Peter K. T. Pang, Jie Shan
  • Patent number: 5278146
    Abstract: Analogs of CRF, which are based upon hCRF, oCRF, sauvagine and alpha-helical CRF, are disclosed that can be administered to achieve a substantial elevation of ACTH, .beta.-endorphin, .beta.-lipotropin, other products of the pro-opiomelanocortin gene and corticosterone levels and/or an increase in blood pressure over an extended period of time. One CRF agonist which has been found to be particularly potent is: H-Ser-Gln-Glu-Pro-Pro-Ile-Ser-Leu-Asp-Leu-Thr-D-Phe-His-Leu-Leu-Arg-Glu-Va l-Leu-Glu-Met-Thr-Lys-Ala-Asp-Gln-Leu-Ala-Gln-Gln-Ala-His-Ser-Asn-Arg-Lys-L eu-Leu-Asp-Ile-Ala-NH.sub.2. In these agonist analogs, one or more of the first six N-terminal residues may be deleted and/or the N-terminal alpha-amino group may be acylated by an acylating agent containing up to 7 carbon atoms. A number of other substitutions may also be made throughout the chain.
    Type: Grant
    Filed: June 29, 1992
    Date of Patent: January 11, 1994
    Assignee: The Salk Institute for Biological Studies
    Inventors: Jean E. F. Rivier, Wylie W. Vale, Jr.
  • Patent number: 5239059
    Abstract: A biologically active peptide which includes the following structure:R.sub.1 --R.sub.1 --R.sub.1 --R.sub.3 --R.sub.5 --R.sub.1 --R.sub.1 --R.sub.1 --R.sub.1 --R.sub.1 --R.sub.2 --R.sub.2 --R.sub.1 --R.sub.1 R.sub.3 --R.sub.1 --R.sub.4 --R.sub.1 --R.sub.3 --R.sub.4 --R.sub.1 --R.sub.1.R.sub.1 is a hydrophobic amino acid, R.sub.2 is a basic hydrophilic amino acid, and R.sub.3 is a neutral hydrophilic amino acid, R.sub.4 is a hydrophobic or basic hydrophilic amino acid, and R.sub.5 is a hydrophobic, basic hydrophilic, or neutral hydrophilic amino acid.Examples of such peptides include the following:(SEQ ID NO:1)--NH.sub.2 ;(SEQ ID NO:2)--NH.sub.2 ;(SEQ ID NO:3)--NH.sub.2 ;(SEQ ID NO:4)--NH.sub.2 ;(SEQ ID NO:5)--NH.sub.2 ;(SEQ ID NO:6)--NH.sub.2 ;(SEQ ID NO:7)--NH.sub.2 ; and(SEQ ID NO:8).The peptides may be employed in pharmaceutical compositions.
    Type: Grant
    Filed: May 10, 1991
    Date of Patent: August 24, 1993
    Assignee: The Children's Hospital of Philadelphia
    Inventors: Michael Zasloff, U. Prasad Kari, W. Lee Maloy
  • Patent number: 5234907
    Abstract: Vasoactive intestinal compound analogs containing substitutions of appropriately selected amino acids at specific positions of the VIP molecule.
    Type: Grant
    Filed: April 24, 1991
    Date of Patent: August 10, 1993
    Assignee: Hoffmann-La Roche Inc.
    Inventor: David R. Bolin
  • Patent number: 5229489
    Abstract: Peptide derivatives of the following general formula (I): Seq. ID Nos. 1-6. ##STR1## wherein AAA is deletion or Ser, BBB is deletion or Glu, CCC is deletion, Ile, Phe, Leu, cyclohexylalanine, D-alle or Lys substituted at the .epsilon.-position by C.sub.6 -C.sub.18 alkylcarbonyl group, DDD is Gly or Gln, EEE is Leu, Nle or Phe, FFF is Met, Leu or Nle, GGG is Ala, Ser, Leu, Asn, Asp or Gln, HHH is Leu, Glu or Lys, III is His, Lys or Arg, JJJ is His, Lys or Arg, Xaa is Ala modified at the carboxy terminal with an amino group, provided that CCC and DDD may independently be modified at the amino terminal by C.sub.2 -C.sub.
    Type: Grant
    Filed: April 12, 1991
    Date of Patent: July 20, 1993
    Assignee: Mitsubishi Kasei Corporation
    Inventors: Tatsuhiko Kanmera, Akihisa Mori, Yoshihide Nakao, Toshihiko Minegishi
  • Patent number: 5217953
    Abstract: The present invention relates to a peptide encoding an antagonist of VIP. The invention also relates to a method of using said peptide to antagonize VIP function. The invention further relates to a pharmaceutical composition.
    Type: Grant
    Filed: November 30, 1990
    Date of Patent: June 8, 1993
    Assignee: The United States of America as represented by the Secretary of the Department of Health & Human Services
    Inventors: Illana Gozes, Douglas E. Brenneman, Mati M. Fridkin, Terry Moody
  • Patent number: 5214031
    Abstract: Disclosed are a growth-inhibitory factor which is a pure protein extracted from human brain and having inhibitory action against neurotrophic activity and a cDNA coding for a protein existing in human brain and the lysate from E. coli transfected with the cDNA having growth-inhibitory action, and also a method of inducing growth-inhibiting activity for treatment of Alzheimer disease by using the protein.
    Type: Grant
    Filed: May 6, 1991
    Date of Patent: May 25, 1993
    Inventor: Yoko Uchida
  • Patent number: 5175251
    Abstract: Human laminin B.sub.1 peptides have been produced. The invention provides novel peptides which contain substantial amino acid sequence similarity to amino acids 897 to 936 in the human sequence. These peptides have been found to have enhanced antimetastatic activity.
    Type: Grant
    Filed: October 29, 1991
    Date of Patent: December 29, 1992
    Assignee: SRI International
    Inventors: Paul H. Johnson, Jerome B. Lazar, David G. Streeter
  • Patent number: 5142025
    Abstract: Novel recombinant HTLV-III fusion proteins denoted R10, PB1, 590, KH1, and the HIV portion of each of these proteins are useful in the diagnosis, prophylaxis or therapy of AIDS. Protein R10 is a 95 kD fusion protein; protein PB1 is a 26 kD fusion protein; protein 590 is an 86 kD fusion protein; and protein KH1 is a 70 kD fusion protein. These proteins are considered to be especially useful to prepare vaccines for the HTLV-III virus.
    Type: Grant
    Filed: September 24, 1990
    Date of Patent: August 25, 1992
    Assignee: Repligen Corporation
    Inventors: Scott D. Putney, Debra Lynn, Kashayar Javaherian, William T. Mueller, John Farley
  • Patent number: 5141924
    Abstract: Vasoactive intestinal peptide analogs containing substitutions of appropriately selected amino acids at specific positions of the VIP molecule.
    Type: Grant
    Filed: June 30, 1989
    Date of Patent: August 25, 1992
    Assignee: Hoffmann-La Roche, Inc.
    Inventor: David R. Bolin
  • Patent number: 5128242
    Abstract: The present invention relates to peptides having adenylate cyclase stimulating activity. The peptides all have at least the sequence His-Ser-Asp-Gly-Ile-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr- Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Ala-Ala-Val-Leu-.
    Type: Grant
    Filed: June 19, 1989
    Date of Patent: July 7, 1992
    Assignee: The Administrators of the Tulane Educational Fund
    Inventors: Akira Arimura, Atsuro Miyata
  • Patent number: 5114843
    Abstract: The present invention relates to the use of peptide analogues as inhibitors of their respective naturally occurring peptides. The structure of the peptide analogues is exemplified by an internal region of the N-terminus of humoral hypercalcemic factor hHCF, and truncations thereof: hHCF(14-34)NH.sub.2, hHCF(13-34)NH.sub.2, hHCF(12-34)NH.sub.2, hHCF(11-23)NH.sub.2, hHCF(10-34)NH.sub.2, hHCF(9-34)NH.sub.2, hHCF(8-34)NH.sub.2 and various amino acid substitutions.
    Type: Grant
    Filed: February 25, 1991
    Date of Patent: May 19, 1992
    Assignee: Merck & Co., Inc.
    Inventors: Michael Rosenblatt, Roberta L. McKee, Michael P. Caulfield, Ruth F. Nutt
  • Patent number: 5112808
    Abstract: This invention provides novel growth hormone-releasing peptides and a method for increasing the release and raising the levels of growth hormone in mammals. The invention also provides a method for increasing the growth rate of meat producing animals, treating the symptoms of growth hormone deficiencies in mammals and improving the efficiency of feed utilization by meat producing and dairy animals.
    Type: Grant
    Filed: May 10, 1988
    Date of Patent: May 12, 1992
    Assignee: American Cyanamid Company
    Inventors: David H. Coy, William A. Murphy
  • Patent number: 5109111
    Abstract: Several known members of the corticotropin releasing factor (CRF) family have been synthesized and tested, including human and rat CRF which have the formula: H-Ser-Glu-Glu-Pro-Pro-Ile-Ser-Leu-Asp-Leu-Thr-Phe-His- Leu-Leu-Arg-Glu-Val-Leu-Glu-Met-Ala-Arg-Ala-Glu-Gln- Leu-Ala-Gln-Gln-Ala-His-Ser-Asn-Arg-Lys-Leu-Met-Glu- Ile-Ile-NH.sub.2. Peptides are herein disclosed that are potent competitive antagonists of CRF in mammals. One which has been found to be particularly potent is: H-D-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-Nle-Ala- Arg-Ala-Glu-Gln-Leu-Ala-Gln-Gln-Ala-His-Ser-Asn- Arg-Lys-Leu-Nle-Glu-Ile-Ile-NH.sub.2. One that has shown particularly prolonged duration of potency is: H-D-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-Nle-Ala- Arg-Ala-Glu-Gln-Leu-Ala-Gln-Gln-Ala-His-Ser-Asn- Arg-Lys-CML-Nle-Glu-Ile-Ile-NH.sub.2.
    Type: Grant
    Filed: March 23, 1990
    Date of Patent: April 28, 1992
    Assignee: The Salk Institute for Biological Studies
    Inventors: Jean E. F. Rivier, Wylie W. Vale, Jr., Catherine L. Rivier, Jean-Francois Hernandez
  • Patent number: 5093233
    Abstract: The present invention relates to the use of peptide hormone analogues as inhibitors of their respective naturally occurring peptide hormone. The structure of the peptide hormone analogues is exemplified by parathyroid hormone (PTH), wherein Lys.sup.13 is substituted to increase the biological activity of the PTH analogues. Thus, there are disclosed peptides having the formulae:PTH(7-34)NH.sub.2 ;[Tyr.sup.34 ]PTH(7-34)NH.sub.2 ;[D-Trp.sup.12, Tyr.sup.34 ]PTH(7-34)NH.sub.2 ;[Nle.sup.8,18, D-Trp.sup.12, Tyr.sup.34 ]PTH(7-34)NH.sub.2 ;[Nle.sup.8,18, Tyr.sup.34 ]PTH(7-34)NH.sub.2 ;desamino[Nle.sup.8,18, D-Trp.sup.12, Tyr.sup.34 ]PTH(7-34)NH.sub.2 ; and,desamino[Nle.sup.8,18, D-Trp.sup.12, Tyr.sup.34 ]PTH(8-34)NH.sub.2wherein Lys.sup.13 is modified in the epsilon-amino acid group by N,N-diisobutyl or 3-phenylpropanoyl.
    Type: Grant
    Filed: April 25, 1990
    Date of Patent: March 3, 1992
    Assignee: Merck & Co., Inc.
    Inventors: Michael Rosenblatt, Eliahu Roubini, Michael Chorev, Ruth F. Nutt
  • Patent number: 5087561
    Abstract: The present invention relates to the use of peptide analogues as inhibitors of their respective naturally occurring peptides. The structure of the peptide hormone analogues is exemplified by human humoral hypercalcemic factor (hHCF), wherein Lys.sup.13 or Lys.sup.11 is modified on the epsilon-amino group by biotin so as to produce HCF analogues which can inhibit the action of HCF.
    Type: Grant
    Filed: June 28, 1990
    Date of Patent: February 11, 1992
    Assignee: Merck & Co., Inc.
    Inventors: Michael Rosenblatt, Michael Chorev, Eliahu Roubini, Ruth F. Nutt, Le T. Duong
  • Patent number: 5087562
    Abstract: The present invention relates to the use of peptide analogues as inhibitors of their respective naturally occurring peptides. The structure of the peptide hormone analogues is exemplified by human humoral hypercalcemic factor (hHCF), wherein Lys.sup.13 is modified so as to produce HCF analogues which can inhibit the action of HCF.
    Type: Grant
    Filed: April 25, 1990
    Date of Patent: February 11, 1992
    Assignee: Merck & Co., Inc.
    Inventors: Michael Rosenblatt, Eliahu Roubini, Michael Chorev, Ruth F. Nutt